Christopher Somerville is listed as a director on 3 SEC Form D filings by 1 issuer between Jun 2016 and Dec 2016: RedLeaf Biologics, Inc. (Lexington, KY — biotechnology — 2016; $750K reported sold to 8 investors).
What this means One deal on file with the SEC, filed Dec 2016. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Christopher Somerville and found 7 differences, 3 worth asking the sponsor about: Amount sold went down between filings; Form D filed 116 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.